Gilead and Arcus to Present P-II Study (ARC-7) Results of Domvanalimab for Non-Small Cell Lung Cancer at ASCO Plenary 2022
Shots:
- The 4th interim analysis of the P-II study (ARC-7) evaluates domvanalimab as monotx. & combination with zimberelimab (doublet), domvanalimab + zimberelimab & etrumadenant (triplet) vs zimberelimab monotx. in a ratio (1:1:1) in 150 patients with m-NSCLC with PD-L1 TPS ≥50% & no EGFR or ALK mutations
- At the data cutoff, improvements in m-PFS in doublet & triplet combinations with a median follow-up time for the efficacy of ~12mos., 45% reduction in risk of disease progression or death for the doublet & 35% for triplet
- For zimberelimab monotx./domvanalimab-doublet & triplet, ORR was 27%/41% & 40%; 6mos. PFS rate (43%/65% & 63%); m-PFS (5.4/12.0 & 10.9mos.), respectively, no unexpected safety signals were seen & overall safety profile consistent with each individual
Ref: Businesswire | Image: Gilead
Related news :- Taiho Exercised its Option to License Arcus’s Domvanalimab and AB308 for NSCLC in Japan and Other Countries
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
